Compare Abbott Laboratories (ABT) vs Core and Main Inc (CNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Core and Main Inc — how do they compare? Abbott Laboratories trades at $109.52 (market cap $187.95B), while Core and Main Inc trades at $45.65 (market cap $8.73B). The key difference: Abbott Laboratories is far larger — about 21.5× Core and Main Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Core and Main Inc pays none. Which is the better fit depends on your goals.
| ABT | CNM | |
|---|---|---|
Market Cap | $187.95B | $8.73B |
Sector | Health | Technology |
52-Week High | $136.62 | $66.98 |
52-Week Low | $82.57 | $42.37 |
Enterprise Value | $214.96B | $11.02B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Core & Main (CNM) trades at $45.85, down 0.97% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings of $0.57 per share, beating estimates, and maintains solid fundamentals including a 23.73% ROE and 5.87% net margin. Recent news highlights institutional activity, such as California State Teachers Retirement System increasing its stake by 22.3% in Q1 2026 (Defense World, 2026-08-04).
The outlook is positive with analyst consensus at 57% buy ratings, supported by revenue growth to $7.6B in 2026 and expanding margins. Risks include high debt levels at $2.24B long-term and competitive pressures in the tools sector. Investors should monitor execution against FY26 guidance of $7.8–$7.9B revenue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Core and Main Inc
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →
